in this issue
Regions :: Western Europe :: U.K.
Lonza and Eclipse Therapeutics Sign Development and Manufacturing Deal
12:06 AM MST | February 29, 2012 | Deepti Ramesh
Lonza says it has signed an agreement with private biotechnology company Eclipse Therapeutics (San Diego, CA) for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Lonza’s light path development services. ET-101 is under investigation for the inhibition of the growth of cancer stem cells. Lonza will produce phase 1 clinical material at its development and manufacturing facility at Slough, U.K., under the deal. Cancer stem cells are a small subset of cells within a tumor that are thought to play a critical role in tumor...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee